One of the sectors where the biopharmaceutical industry is growing the most is that of small biotech companies, located mainly in some US hubs: Washington, Philadelphia, Greater New York, Chicago, San Diego, South San Francisco, and Boston.
To meet their needs, Stevanato Group plans to open a Technology Excellence Center (TEC) in Boston, Massachusetts, in the second half of 2020.
Last week the construction work of the area in Seaport District in Boston that will host the center started and it was marked by the visit of our CEO, Franco Stevanato. In a kick off meeting, he discussed the plan of construction and implementation of services with Abizer Harianawala, US TEC site leader, Howard Drake, Vice President Business Development and Relationship Management in the US and members of the infrastructure and laboratory team.
TEC will initially provide analytical and testing services related to the container closure system and drug delivery devices complemented by customized services for Biopharma Companies’ drug formulation and manufacturing process. TEC is a consolidation of the success experience of SG Lab in Europe. By teaming up with a network of partners, it plans to add more capabilities providing a comprehensive offer along the drug life cycle including R&D, project management and regulatory support.
“The center will initially have a highly skilled team in the area of primary containers, which will be able to help customers in the choice of the best container for their drug. It will also feature a lab performing critical analytical tests for characterizing the container-closure system. In the coming years, customers will find in TEC all the competencies also for the drug delivery devices, and in general will find in Stevanato Group a competent partner always listening and looking for solutions,” says Paolo Patri, Chief Technology Officer at Stevanato Group.
“TEC is a big step forward in the vision of the Group as a full solution provider. Thanks to it, we will be able to work together with the developers of new molecules at an early stage or in Phase I. We will offer them all our capabilities in terms of glass primary packaging knowledge and delivery devices, in a partnership that will go beyond our traditional role of suppliers,” says Franco Stevanato.